calibrated to 1.1% population-level MG prevalence. We modelled the potential impact of using the ResistancePlus MG test (SpeeDx; Sydney, Australia) for symptomatic patients. We conducted sensitivity analyses varying the clearance rate (23-44 days) and percent of infections that are symptomatic in women (0%-11.7%). Results The model estimated a per-partner MG transmission probability of 0.042. The model predicted that implementing the ResistancePlus test for symptomatic patients would increase

more »

... e percent of MG infections that are macrolide-susceptible from 50% to 85% in 2 years. In sensitivity analyses, transmission probability estimates and 2 year percent of MG infections that are macrolide-susceptible varied from 0.032-0.047 and 82%-92%, respectively. Conclusion Directing treatment based on aetiology and known macrolide resistance may preserve the ability to treat MG with azithromycin. Moxifloxacin therapy could be limited to patients with known macrolide-resistant MG infection and prevent treatment failure for those patients.